EE668 Empagliflozin for the Treatment of Adult Patients With Symptomatic Chronic Heart Failure With Reduced Ejection Fraction (HFREF): A Cost-Effectiveness Analysis From the Italian NHS Perspective
Abstract
Authors
GL Colombo S Di Matteo G Bruno C Martinotti S Linden